No Data
No Data
The Tokyo Stock Exchange Growth Market 250 index rebounded, with solid market conditions for leading stocks such as GENDA.
Tokyo Stock Exchange Growth Market Index 819.08 +10.17 / volume 0.2 billion 9.82 million shares / trading value 132.9 billion yen Tokyo Stock Exchange Growth Market 250 Index 639.19 +8.45 / volume 0.1 billion 36.65 million shares / trading value 98.5 billion yen Today's growth market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index rebounded. The number of stocks that rose in price was 281, the number of stocks that fell was 270, and the unchanged number was 35. The US stock market on the 21st rebounded. The Dow Jones Average was up 55.52 points (+0.
The TOPIX Global Market 250 index rebounded significantly, with investor sentiment improving and recovering in the 600-point range.
Tokyo Stock Exchange Growth Market Index: 783.95 +18.93 / Volume: 0.3 billion 28.04 million shares / Trading value: 136.3 billion yen. TSE Growth Market 250 Index: 609.11 +16.37 / Volume: 0.2 billion 12.49 million shares / Trading value: 98 billion yen. Today's growth market: the TSE Growth Market Index rose for the 8th consecutive day, while the TSE Growth Market 250 Index rebounded. There were 424 advancing stocks, 143 declining stocks, and 21 unchanged stocks. The U.S. stock market continued to rise on the 15th. The Dow Average rose by 554.67 dollars.
Japan Post's operating profit in the first quarter increased by 22.2% to 211.4 billion yen.
Japan Post Holdings Co., Ltd. (6178) announced its first quarter results for the fiscal year ending March 2025. Operating revenue decreased by 3.9% YoY to 2.735888 trillion yen, while operating profit increased by 22.2% YoY to 211.449 billion yen. The increase in investment income at Yucho Bank (7182), a subsidiary, and the improvement in capital gains and losses at Japan Post Insurance Co., Ltd. (7181) were contributing factors. Operating revenue for the fiscal year ending March 2025 is expected to decrease by 5.9% YoY to 11.280 trillion yen, while operating profit is expected to increase by 13.7% YoY to 760 billion yen.
OncoTherapy Science: Announcements of individual stocks regarding the occurrence of non-operating expenses.
OncoTherapy Science: 1st quarter financial results SMS for the March 2025 period based on Japanese standards (consolidated).
OncoTherapy Science 1Q Loss Y302.00M Vs Loss Y400.00M
No Data